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Abstract: Enterohemorrhagic E. coli (EHEC) causes severe diseases in humans 
worldwide. One of its virulence factors is EspP, which belongs to the serine protease 
autotransporters of Enterobacteriaceae (SPATE) family. In this review we recapitulate the 
current data on prevalence, biogenesis, structural properties and functionality. EspP has 
been used to investigate mechanistic details of autotransport, and recent studies indicate 
that this transport mechanism is not autonomous but rather dependent on additional factors. 
Currently, five subtypes have been identified (EspPα-EspPε), with EspPα being associated 
with highly virulent EHEC serotypes and isolates from patients with severe disease. EspPα 
has been shown to degrade major proteins of the complement cascade, namely C3 and C5 
and probably interferes with hemostasis by cleavage of coagulation factor V. Furthermore, 
EspPα is believed to contribute to biofilm formation perhaps by polymerization to  
rope-like structures. Together with the proteolytic activity, EspPα might ameliorate host 
colonization and interfere with host response. 
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1. Introduction 
The plasmid-encoded extracellular serine protease EspP is one of the most abundant proteins in 
culture supernatants of Shiga-toxin producing Escherichia coli (STEC) and enterohemorrhagic E. coli 
(EHEC) [1,2] and has been first described on the large plasmid pO157 of EHEC O157:H7 strain 
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EDL933 [1]. The espP gene consists of a 3900 bp open reading frame that encodes the 1300 aa EspP 
protein with a molecular weight of 142 kDa. Cleavage of the N-terminal signal peptide and the  
C-terminal β-domain leads to the mature secreted passenger domain. The mature protein found in the 
extracellular milieu is 104 kDa large and shows serine protease activity [1]. In the same year,  
Djafari et al. described a serine protease of identical size from a bovine E. coli O26:NM strain and 
designated the protein PssA (protease secreted by STEC) [3]. Comparative analysis revealed however 
that EspP and PssA differ by only eight bases on the nucleotide level and a single point mutation on 
the protein level. PssA is thus an isoform of EspP. 
EspP belongs to the family of serine protease autotransporters of Enterobacteriaceae (SPATE) [1] 
and has been used as a prototype to study the autotransport mechanisms. An early definition of this 
secretion system suggested that autotransporters harbor all components required for translocation 
through the inner and outer membrane within one entity [4–6]. However, various recent studies have 
demonstrated the interaction with further accessory factors [7–12], indicating that autotransport is not 
independent and might be a misnomer. More than 1500 members of the autotransport family have been 
identified, probably forming the largest group of proteins secreted by Gram-negative bacteria [13]. 
Autotransporters show considerable structural and functional differences and include adhesins, 
proteases and lipases. As indicated by their name, SPATEs exhibit serine protease activity and are 
secreted by Enterobacteriaceae. Although some SPATEs have been found in non-pathogenic  
bacteria [14] they are clearly associated with pathogenic organisms [6,15–18]. Table 1 shows selected 
SPATE proteins from pathogenic E. coli [19,20]. 
Table 1. Selected serine protease autotransporters of Enterobacteriaceae (SPATEs) in 
pathogenic E. coli. ETEC, enterotoxigenic E. coli, EPEC, enteropathogenic E. coli,  
APEC, avian pathogenic E. coli, UPEC, uropathogenic E. coli, EAEC enteroaggregative  
E. coli, DEAC diffusely aggregating E. coli. 
Protein Organism Function/Effects Reference 
EatA (ETEC autotransporter A) ETEC Mucosal destruction [21] 
EpeA (EHEC plasmid-encoded autotransporter) EHEC Mucinase activity [22] 
EspC (EPEC secreted protein C) EPEC 
Mediation of EPEC lysozyme 
resistance, vacuolation, cell 
rounding and detachment, 
cytoskeletal damage 
[23–25] 
EspI (E. coli secreted protease, island-encoded) STEC Unknown [26] 
EspP/PssA (extracellular serine protease, 
plasmid-encoded/protein secreted by STEC A) 
EHEC See this review [1,3] 
Hbp/Tsh (hemoglobin protease/ 
temperature-sensitive hemagglutinin) 
Human septic  
E. coli/APEC/ 
UPEC 
Binding of hemoglobin/heme, 
degradation of hemoglobin, 
hemagglutinin, adhesion, 
mucinase activity 
[27–31] 
Pet (plasmid-encoded toxin) EAEC 
Inflammation, mucus secretion, 
tissue damage 
[32,33] 
Pic/PicU (protease involved in intestinal 
colonization) 
EAEC/UPEC 
Hemagglutinin, serum resistance 
mediator, mucinase activity 
[34,35] 
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Table 1. Cont. 
Protein Organism Function/Effects Reference 
Sat (secreted autotransporter toxin) 
DAEC/EAEC/ 
UPEC 
Causes autophagy, vacuolating 
toxicity, cell detachment and 
elongation, formation of lesions 
in tight-junctions 
[18,36–39] 
SepA (Shigella extracellular protein) EAEC 
Tissue inflammation, mucosal 
atrophy, fluid accumulation 
[40,41] 
SigA (Shigella IgA-like protease homolog) EAEC Cell rounding and detachment [40,42] 
Vat (vacuolating autotransporter toxin) APEC Vacuolating toxicity [43] 
In general, SPATE proteins are believed to contribute to the virulence of their bacterial host by the 
secreted passenger domains which all harbor the serine protease motif GDSGS (with S being the 
catalytic serine residue). Despite the overall similar fold, it appears that substrate specificity is distinct 
for the known SPATEs and that these differences at least partially translate into distinct biological 
functions [23,34,36,44–46] (Table 1).  
For EHEC, Shiga toxins are regarded as major virulence factors which are however not sufficient 
per se for high pathogenicity. Additional virulence factors are necessary that mediate bacterial 
adherence or interfere with the host response [47,48]. This is exemplified by strains that lack  
LEE-encoded virulence factors and often show mild clinical outcomes probably due to insufficient 
adherence. However, bacterial adherence can also be mediated by other factors as observed in the 
European E. coli O104:H4 outbreak in 2011. In fact, this outbreak suggests that different “recipes” for 
high virulence do exist for this pathogen [40]. Concerning EspP, there are different subtypes from which 
the translocation-competent and proteolytically active subtype EspPα is associated with isolates from 
patients with severe disease [49,50]. EspPα is therefore considered as additional EHEC virulence factor. 
2. Extracellular Serine Protease Plasmid-Encoded 
2.1. Organization of EspP  
EspP consists of a 55 aa N-terminal signal peptide (SP), the secreted passenger domain (PD, amino 
acids 56–1023) and the C-terminal β-domain, also called translocator, which is 277 amino acids in 
length [1] (see Figure 1). This structural organization is seen in all SPATEs. The serine protease motif 
is located in the PD (see 2.4), while the β-domain is responsible for efficient autotransport through the 
outer bacterial membrane (see 2.3). The C-terminal part of the PD harbors the approximately 30 aa 
linker-region that connects the β-domain and the PD and is necessary for folding and stability of the  
β-domain [51–53]. In addition, the autochaperone motif (AC) at the passenger C-terminus is essential 
for folding of the β-helical structure of the passenger domain [54,55]. 
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Figure 1. Structural organization of EspP. Signal peptide, amino acids 1–55; passenger 
domain, amino acids 56–1023; β-domain, amino acids 1024–1300. α-linker, α-helix 
connecting the passenger domain and the β-domain, amino acids 1014–1028;  
AC, autochaperone domain which is part of the passenger domain. Autoproteolytic 
cleavage occurs between Asn1023 and Asn1024. 
 
2.2. Autotransport 
At least seven different pathways exist for the protein transport in Gram-negative bacteria [56]. 
Autotransport, also referred to as Type V pathway, is probably the most widely distributed mechanism 
and is divided into classical autotransport (also known as Type Va), the two-partner secretion system 
(Type Vb), and the trimeric autotransporters (TAA, Type Vc) as well as the two recently described 
autotransporter Types Vd and Ve [57]. Briefly, the transport through the inner membrane (IM) is 
mediated by the N-terminal signal peptide via the Sec-machinery in the Type V pathway and the  
C-terminal β-domain is inserted into the outer membrane (OM) and facilitates secretion of the 
passenger domain into the extracellular space. EspP is transported by the Type Va secretion system, 
and it has to be noted that biogenesis via Type Va secretion apparently shows some diversity in 
SPATE. We will therefore limit the discussion to novel mechanistic details of EspP biogenesis, which 
not necessarily fully applies to other SPATE. 
EspP has an unusually long SP which is found in about 10% of autotransporters and which has been 
shown to facilitate posttranslational targeting [58]. The C-terminal part resembles a typical SP with 
canonical N, H, and C regions (termed N2, H2, and C) while the N-terminal part harbors a unique 
sequence motif (N1 and H1) that is highly conserved among SPATEs from E. coli and  
Shigella sp. [59,60]. The N-terminal extension is not required for efficient translocation across the IM. 
However, modifications of the SP lead to misfolding of EspP in the periplasm and inhibition of 
translocation across the OM. The SP transit via the Sec pathway is relatively slow and it is believed 
that this is due to tethering of the PD to the IM [61] and a slow dissociation from the IM probably due 
to an unusual conformation of the SP [58]. EspP interacts with several chaperones in the periplasm, 
namely SurA, Skp, DegP, FkpA, and the Bam complex [7–9]. A direct protein-protein interaction of 
SurA, DegP [8] and FkpA [9] has been observed with the unfolded but not with the native folded PD 
of EspP, and it has been shown that surA and skp mutants moderately reduce secretion while in a degP 
mutant translocation was abolished [8]. Interestingly, DegP acts as a chaperone and as serine 
endoprotease that degrades unfolded proteins. Interaction with chaperones probably prevents 
misfolding and keeps the PD in a loosely folded translocation-competent state [8,53] and probably 
prevents DegP-mediated degradation. Skp binds to the PD before translocation while SurA binds 
during the transit across the OM through a pore inside the β-domain [10]. The β-domain is highly 
conserved among SPATEs [20] and consists of a 12-stranded β-barrel, a short N-terminal α-helix, and 
a short linker loop [62] (Figure 2). 
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Figure 2. EspP β-domain. The EspP β-domain (residues 1024–1300) forms a 12-stranded 
β-barrel with a short α-helix and a linker loop at its N-terminus. Secondary structure 
elements are colored in the ribbon diagram: yellow (β-strand), red (α-helix), and green 
(loop). Some residues (1074–1075, 1135–1137, 1184–1191) are missing in the crystal 
structure and are therefore omitted [62]. 
 
The β-barrel domain shows considerable tertiary structure in the periplasm and during membrane 
integration [53], which might also be achieved by interactions with periplasmic chaperones. As with 
the PD, SurA, DegP [8], and Skp [10] interact with the β-domain. In addition, the Bam complex 
catalyzes protein assembly into the OM [7]. Ieva et al. suggested that Skp interacts with EspP on the 
periplasmic side as it translocates the IM and transfers it to SurA. SurA subsequently binds to BamA, 
which together with BamB and BamD interacts with the β-domain. The lipoprotein components of the 
Bam complex facilitate the assembly into the OM. Notably, secretion of the PD is initiated before  
β-domain assembly is complete [10]. The PD is translocated in a C- to N-terminal direction across the 
β-barrel domain [7]. When a C-terminal ~17 kDa segment is exposed to the cell surface folding of the 
PD is initiated. This traps the PD outside the cell and also provides at least part of the energy necessary 
for the translocation process. Folding might be the rate-limiting step in EspP biosynthesis [63]. After 
complete translocation of the PD to the extracellular milieu, the PD is cleaved from the β-domain 
within the pore of the β-barrel in the OM [10,62,64]. Passenger domains can be released from the  
β-domain by extracellular proteases or—as in the case of EspP—autocatalytically. EspP is cleaved 
between Asn1023 and Asn1024, a cleavage site that is highly conserved among SPATEs [55,64]. In the 
first mechanistic study, it has been suggested that the carboxyl group of Asp1120 activates Asn1023 
within the β-barrel pore [64]. The Asn1023 amide group mediates a nucleophilic attack on the scissile 
bond between Asn1023 and Asn1024 thereby forming a succinimide that is further hydrolyzed into Asn 
and iso-asparagine via a cyclic intermediate [64] (Figure 3b). Asparagine cyclization is in general slow 
in peptides, underlining the catalytic mechanism of this reaction. Notably, residues important for 
autoproteolysis are conserved in all SPATEs suggesting a common cleavage mechanism. Barnard et al. 
demonstrated that the conserved residues E1021–L1032 (which are part of the α-helix that spans the  
PD-β-domain junction) constrain the active site asparagine to conformations favorable for cyclization. 
In addition to steric effects, positively charged residues in the α-helix interact with negatively charged 
residues on the barrel wall facing the lumen. This leads to formation of a salt bridge that is essential for 
the cleavage reaction [65]. Mutations inside the α-helix abolished autocatalytic cleavage whereas 
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passenger translocation of EspP was not affected [66]. However, in Hbp/Tsh comparable mutations 
impaired both cleavage and translocation [67]. Interestingly, a recent study has demonstrated that in 
Hbp/Tsh the active Asn1100 (which is equivalent to Asn1023 in EspP) is not activated by the respective 
Asp1197 residue [68]. Instead, Tyr1227 and Glu1249 position a water molecule in proximity to Asn1100, 
resulting in deprotonation and activation of this residue [68]. A similar model has been proposed 
recently for EspP, where the nucleophilicity of the active site asparagine is enhanced by proton 
abstraction via water molecules that are positioned by the conserved acidic residues Asp1120, Glu1154 
and Glu1172 [65]. The resulting oxyanion intermediate is stabilized by protonated Glu1172 [65]. The 
newly formed N-terminus of the β-barrel (Asn1024) interacts with an acidic cluster and the α-helix and 
the linker loop block access from the periplasmic space, which probably protects the bacterium from 
uncontrolled influx and efflux [62]. Whether the recently identified translocation and assembly module 
(TAM) that contributes to secretion of the autotransporters Ag43, EhaA, and p1121 [11] also is 
involved in secretion of EspP remains to be investigated. The complete secretion of EspP is illustrated 
in Figure 3. 
Figure 3. Model of EspP biogenesis. (a) Schematic representation of EspP secretion. EspP 
is translocated across the inner membrane via the sec machinery. Binding of several 
chaperones stabilizes EspP in a loosely-folded state in the periplasm. The β-barrel is 
inserted into the outer membrane by the Bam complex and other chaperones. Folding of 
EspP occurs in the extracellular space. When translocation across the outer membrane is 
complete, the passenger domain is cleaved from the β-domain autoproteolytically and 
transported into the extracellular space. IM, inner membrane; OM, outer membrane;  
SP, signal peptide; PD, passenger domain; β, β-domain; Bam, Bam complex, for clarity, 
only the A subunit is shown; (b) Proposed model of the autoproteolytic cleavage. The 
peptide bond between the passenger domain (Asn1023) and the β-domain (Asn1024) is 
cleaved inside the β-barrel. The amide group of Asn1023 mediates a nucleophilic attack on 
the peptide bond, which is catalyzed by a water molecule that forms hydrogen bonds with 
Glu1154 and other acidic residues (not shown). The intermediate oxyanion is stabilized by 
Glu1172 and results in formation of succinimide and release of Asn1024 as neo-N-terminus. 
The succinimide intermediate is eventually hydrolyzed to asparagine and iso-asparagine; 
dashed lines, hydrogen bonds [8,10,64,65]. 
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Figure 3. Cont. 
 
2.3. Prevalence and Distribution of EspP  
The espP gene has been first described on the large plasmid of O157:H7 EHEC strain EDL 933 [1] 
and since then, distribution and prevalence in different E. coli populations has been investigated 
intensively. In general, espP is strongly associated with STEC, EHEC and atypical enteropathogenic  
E. coli (EPEC) and has been detected only very rarely in other E. coli pathotypes and, to the best of our 
knowledge, not in commensal E. coli [18,69,70]. The espP gene was found in one study in 3.6% of the 
analyzed EAEC strains [18] and in 1.4% of typical EPEC [70]. Generally speaking, highest 
prevalences of espP have been seen in classical EHEC serotypes such as O157:H7, O26:H11/NM, or 
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O145:H25/H28/NM [49,50,71–74]. In addition to pO157, espP has been described on the virulence 
plasmids pO113 [22], and pO26-Vir [75]. Interestingly, espP is not found in sorbitol-fermenting 
(SF)O157:NM and sequence analysis of the respective virulence plasmid has revealed that pSFO157 
encodes the sfp fimbriae gene cluster instead of espP [76]. Similarly, Nagano and coworkers showed 
that β-glucuronidase (GUD+) NSF O157:H7 also do not harbor espP [77]. The respective large plasmid 
in these strains (pO157_2) also lacks espP [78]. 
Besides the variable distribution of espP in virulence plasmids, different espP alleles have been 
described. Brunder et al. first showed seven different restriction types for espP PCR products in a 
limited strain collection indicating a certain degree of heterogeneity [79]. A systematic analysis of 98 
espP-positive EHEC and STEC strains from 56 different serotypes identified four different alleles, 
namely espPα, espPβ, espPγ, and espPδ [49]. The four alleles have been found in 17, 16, 15, and eight 
serotypes, respectively. Notably, the highly virulent serogroups O157, O26, O111, and O145 all 
exclusively harbored espPα. The encoded proteins EspPα and EspPγ are secreted (see 2.2) and 
proteolytically active (see 2.4) while EspPβ is either not secreted or proteolytically inactive, and EspPδ 
is secreted but proteolytically inactive [49], demonstrating significant functional differences of espP 
alleles on protein level. Based on the allele-specific PCR developed in this study, Khan et al. 
investigated 121 espP-positive strains belonging to 61 different serotypes. The serotypes 
O157:H7/NM, O26/H11, and O145:NM again all contained espPα and serotypes with lower virulence 
harbored espPβ or espPγ, espPδ has not been found in the strain collection [50]. Furthermore, espPα 
was more prevalent in human isolates (84%) than in environmental isolates (47%), while espPγ was 
more present in the environment (40%) than in humans (11%) [50], indicating that the environmental 
reservoir of espP-positive strains might differ on subtype-level. It has been suggested that further espP 
alleles might be found due to additional recombination events [49]. In accordance, Bielaszewska et al. 
described a new espP allel, espPε, that was found in one E. coli O91:H8 and 49 of 77 
O91:H14/Hnt/NM [80]. 
Several studies have investigated the correlation of espP in human isolates with disease [72,74,81] 
and suggested that there is no significant correlation between espP and clinical outcome, while others 
found differences in prevalence of the espP gene in clinical isolates and environmental samples [82]. 
These inconsistent results underline that it is not possible to assign the virulence potential of espP 
without taking into account the functional differences of EspP subtypes. Accordingly, Khan et al. 
found the espP gene in 65% of isolates from patients with bloody diarrhea or HUS and in 67% of 
isolates from patients with watery diarrhea or without any symptoms at all. On subtype level however, 
all espP-positive strains from HUS patients harbored espPα, indicating a potential role of this subtype 
in EHEC pathogenicity [50]. It has however to be kept in mind that EHEC quite likely have developed 
different pathways of host injury. 
Concerning the different animal and environmental reservoirs, espP is widely distributed and shows 
a certain association with cattle reservoirs. Toszeghy et al. found the espP gene in 22 of 101 bovine 
isolates but in none of 26 and 19 isolates of chicken and turkey, respectively [83]. Horcajo et al. found 
espP in 60.3% of EHEC and atypical EPEC strains in cattle but just in 11.7% of strains from sheep and 
goat [84]. In accordance, several other studies showed the association of the espP gene with bovine 
isolates with a prevalence of 23.8% to nearly 100% [73,81,84–92]. Furthermore, espP has been found 
in E. coli isolates from food samples like raw-milk, cheese [82,93], meat products [94,95], drinking 
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water, tea [94], and ground beef [96] as well as in environmental isolates, e.g. from soil samples, 
ground, cattle water troughs, and feeders [50,82,97,98]. As indicated, reservoirs of  
espP-positive strains might differ on subtype-level. However most studies have only determined the 
presence of espP and not performed subtype-specific analysis. 
2.4. Proteolytic Activity and Structure of the Passenger Domain 
The passenger domain of EspP harbors a serine protease function as seen by the typical serine 
protease sequence motif GDSGSPLF and by the fact that it is inhibited by addition of 
phenylmethanesulfonylfluoride (PMSF), a specific serine protease inhibitor, but not by addition of 
ethylenediaminetetraacetic acid (EDTA), an inhibitor of metalloproteases [1]. The catalytic triade has 
been determined by site-directed mutagenesis and consists of His127, Asp156, and Ser263 [2]. 
At present, only a limited number of substrates has been identified. These are coagulation factor V, 
porcine pepsin A [1], apolipoprotein A-I [26], complement factor C3/C3b and C5 [99], and  
EHEC-hemolysin [100]. In addition, a casein-based assay has been used to determine proteolytic 
activity of the homologue PssA [3]. Furthermore, EspP has been shown to cleave the synthetic 
peptides Suc-Ala-Pro-Leu-pNA (Suc, succinic acid, pNA, para-nitroaniline) and Arg-Arg-pNA [45]. 
However, the latter could not be reproduced by our own studies and also no EspP substrate has been 
described that is cleaved C-terminal to Arg. Several physiological relevant proteins have been shown 
to resist EspP-mediated degradation namely human IgA, a human myeloma IgA1 preparation, bovine 
serum albumin, alpha-2-macroglobulin, transferrin, lactoferrin, pepsinogen [1], spectrin, bovine 
submaxillary mucin [45] as well as complement factors H and I [99]. 
The cleavage of complement factors has been studied in more detail. Orth et al. demonstrated that 
EspPα cleaves complement factors C3/C3b and C5 by incubation of purified proteins and human 
serum with EspPα and incubation of purified complement proteins with EHEC culture supernatants. 
Factor C3b was degraded into three major fragments with molecular masses of 42, 38, and 37 kDa, 
respectively, while the degradation of factor C5 into three fragments with molecular masses of 39, 37, 
and 33 kDa was found to be less pronounced. C5-depleted serum that was supplemented with purified 
C5 preincubated with EspP showed significantly reduced complement activation in all three activation 
pathways (classical pathway, alternative pathway, mannan-binding lectin pathway) [99]. The 
complement system plays a crucial role in the host response of the innate immune system and 
downregulation of complement activation might consequently impair host defense in EHEC infections. 
It has been suggested that complement downregulation might protect EspPα-secreting EHEC as well 
as host cells from opsonization, complement-mediated lysis, and inflammatory events [99]. Cleavage 
of C3 has been shown for several other bacterial proteases. These include dentilisin from  
Treponema denticola [101], interpain A from Prevotella intermedia [102], extracellular gelatinase 
from Enterococcus faecalis [103], streptococcal pyrogenic exotoxin B from Streptococcus sp. [104], as 
well as proteases from Porphyromonas gingivalis [105], and Pseudomonas aeruginosa [106]. 
Cleavage of C5 has been shown by the 56-kilodalton protease from Serratia marcescens [107], 
gingipain-R and gingipain-K from Porphyromonas gingivalis [108], and streptococcal C5a peptidase 
from Streptococcus sp. [109]. A potential role of EspPα is underlined by the finding that specific 
antibodies have been isolated from sera of HUS patients [1,3]. 
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Another potentially relevant substrate in vivo might be coagulation factor V (FV), which is present 
in plasma and in α-granules of platelets. FV plays a role in hemostasis and can act either as 
procoagulant or as anticoagulant (reviewed in [110]). Brunder et al. have suggested that this 
degradation could lead to decreased coagulation possibly leading to prolonged bleeding and increased 
hemorrhage in the gastro intestinal tract that can be observed during EHEC infection [1]. Together 
with further virulence factors such as EHEC-Hly [111] this might lead to improved supply of iron via 
hemoglobin. The ability to degrade FV is widely distributed within the SPATE family. Pet and Pic 
from EAEC, Sat from UPEC, and EspC from EPEC also cleave this protein. Also, Tsh from avian 
pathogenic E. coli was found to degrade FV when a purified protein was used but not in human  
plasma [45]. Unfortunately, functional investigations have not been performed so far. 
Apolipoprotein A-I (apo A-I) has been reported to be cleaved by EspPα and EspI, another SPATE, 
which is also found in EHEC [26]. However, degradation has not been investigated on a functional 
level. Apo A-I is known to be involved in lipid binding and transport [112]. More interestingly, 
Concha et al. suggested that during bacterial infection apo A-I could release antimicrobial peptides 
from HDL (high density lipoprotein) particles after proteolysis [113]. Furthermore, apo A-I is a 
negative acute phase protein with anti-inflammatory properties [114] that can directly bind 
lipopolysaccharides (LPS) [115] and is capable of inactivating endotoxins and decreasing LPS-induced 
cytokine release [116,117]. Therefore, degradation of apo A-I by EspPα might either activate or inhibit 
its antimicrobial function and could interfere with inflammatory processes during EHEC infection. 
Again, experimental data in model systems concerning the functional implications of apo A-I cleavage 
are missing. 
In addition, it has been demonstrated that EspPα cleaves EHEC hemolysin (EHEC-Hly) in its free 
and vesicle-bound form [100]. EHEC-Hly belongs to the repeat-in-toxin (RTX) family [118] and is 
able to lyse erythrocytes and lymphocytes [118,119] and injures microvascular endothelial cells [120]. 
Functional characterization was performed using purified proteins, supplementation of purified EspPα 
to culture supernatants of EHEC-Hly expressing strains, and coexpression of both proteins [100]. 
Cleavage of EHEC-Hly occurs in the hydrophobic domain which is important for the cytolytic activity 
of RTX toxins [121] and consequently leads to loss of hemolytic activity. In a cellular infection model 
using human brain microvascular endothelial cells (HBMEC), coexpression of EspPα and EHEC-Hly 
in recombinant E. coli resulted in basal HBMEC cytolysis whereas pronounced dose-dependent 
cytolysis was observed in controls [100]. It has been proposed that pathogenic E. coli might be able to 
regulate their virulence phenotypes by interference of effector molecules [100]. While cleavage and 
inactivation has been, to the best of our knowledge, only described so far for EspP and EHEC-Hly, 
other RTX toxins are activated by proteolytic cleavage. For example, various proteases of  
Vibrio cholerae cleave and activate the El Tor cytolysin/hemolysin [122]. Another example is the 
proteolytic activation of Shiga toxins by eukaryotic proteases [123,124]. 
Khan et al. solved the 2.5 Å crystal structure of the EspP passenger domain using the 
proteolytically inactive mutant S263A [125]. It consists of a large β-helical stalk and a globular 
subdomain that harbors the catalytic triad (see Figure 4). The overall fold of EspP is typical for known 
autotransporters and resembles that of E. coli hemoglobin protease (Hbp) [126] and  
Haemophilus influenza immunoglobulin A protease (IgAP) [127]. 
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Figure 4. EspPα passenger domain. (a) Ribbon diagram of the EspPα passenger domain. 
EspPα is composed of a β-helical stalk and three globular subdomains (SD), red, SD 1 
(residues 56–313), blue, SD 3 (residues 596–630), green, SD 4 (residues 671–699), yellow, 
β-helical stalk. In contrast to Hbp and IgAP, EspPα does not exhibit the large SD 2 
protruding from the β-helical stalk. Instead, SD 3 in EspPα is much larger than in Hbp and 
IgAP and shows similarity to a domain termed 2A in Pet [128]. SD 3 exhibits a disordered 
loop containing the only two cysteine residues in the entire passenger. The blue circle 
indicates the position of the catalytic triad; (b) Catalytic triad of EspPα. Top: Overview of 
EspPα. Localization of the detailed view (bottom) is highlighted by the orange rectangle. 
Bottom: Residues of the catalytic triad (H127, D156, and S263) are shown as orange sticks. 
Ser263 is exchanged by Ala in the crystal structure [125]. 
 
The globular subdomain shows similarity to the chymotrypsin family. However, the S1 subsite of 
EspPα is narrower and shallower as well as slightly more hydrophobic than that of bovine 
chymotrypsin. Therefore, Khan et al. suggested that EspPα cleaves after smaller and more 
hydrophobic amino acids than chymotrypsin, which cleaves after tyrosine, tryptophane, phenylalanine, 
leucine, and methionine. This suggestion is in good accordance with the cleavage sites that have been 
determined so far where EspPα mainly cleaves after Leu [1,45,99,100]. When compared to Hbp and 
IgAP, the active site cleft of EspPα is slightly wider and much deeper indicating different substrate 
specificities. Furthermore, it is more exposed than that of Hbp and much more exposed than that of 
IgAP, leading to the suggestion that EspPα interacts with a larger surface of substrates or with larger 
substrates in general [125]. This is in accordance with the finding that EspPα is able to cleave porcine 
pepsin A but not its precursor pepsinogen [1] suggesting that not only the amino acid sequence but also 
the three-dimensional structure might be important for substrate recognition. This might be amongst 
other effects mediated by the β-helical stalk as proposed by Khan et al. [125].  
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Taken together, EspPα seemingly shows high substrate specificity. There are only a few known 
human substrates, which are related to blood coagulation and immune response. Cleavage of these 
substrates might contribute to the severity of EHEC infections. Also, EspP might be involved in 
regulation of E. coli virulence as shown by cleavage of EHEC hemolysin. Cleavage predominantly 
occurs after leucine at position P1 and other small hydrophobic amino acids at position P2. 
2.5. Cytotoxicity and Cellular Adherence 
Cytotoxicity of EspP is discussed controversially. Incubation of Vero cells with culture supernatants 
of PssA secreting E. coli strains resulted in cytotoxic effects as analyzed by fluorescence microscopy 
with phalloidin staining. Dependent on incubation time the cells showed defects in cell-cell junctions, 
retraction of cell bodies, and loss of stress fibers (5 h), with disruption of the actin cytoskeleton in 
about 30% of cells, loss of cell-cell junctions, detachment from the substratum (10 h), and cell death at 
later time points [3]. It was suggested that these effects might be due to apoptosis, however cytotoxic 
pathways have not been analyzed. In contrast, Dutta et al. were not able to reproduce any cytopathic 
effects on Vero cells after incubation with 0.5 and 1 μM EspP for 5–30 h. In addition, no cytotoxic 
effects have been shown for the epithelial cell line HT-29 and HEp-2 in this study [45]. In our own 
studies, we neither found any cytotoxic effects in epithelial HT-29 cells nor in endothelial HBMEC 
after incubation for 30 h or 48 h with up to 1 μM EspPα (Brockmeyer, unpublished data). A recent 
study used the epithelial HeLa cells and observed binding of EspPα after 6 h of incubation in a  
dose-dependent manner [129]. Prolonged incubation (24 h) with EspPα at higher concentrations lead to 
cell rounding in this study. Since EspPα did not induce LDH release, Xicohtencatl-Cortes et al. stated 
that it showed cytopathic but not cytotoxic effects. Again, potential underlying mechanisms have not 
been analyzed. 
Initial motivation to analyze the potential of EspPα to contribute to cellular adherence or biofilm 
formation was raised by the finding that pO157 is required for full adherence of E. coli to Henle 407 
intestinal and HEp-2 epithelial cells [130] and influences the colonization of the bovine terminal 
rectum [131]. In addition, pO157 is important for biofilm formation and adherence to the epithelial 
T84 cells [132]. Puttamreddy et al. generated a transposon insertion library in E. coli strain EDL933 
and identified 51 distinct genes or intergenic regions responsible for biofilm formation. Among the 
genes responsible for full biofilm potential is espPα which also contributed to adherence of T84  
cells [133].  
A potential mechanism for biofilm formation and adherence mediated by EspPα has been published 
recently by Xicohtencatl-Cortes et al. [129]. Under certain conditions, EspPα is able to form 
macroscopic rope-like structures via oligomerization. These ropes are up to 2 cm in length, and show 
pronounced stability against mechanical stress, high temperature, and detergents [129]. Under 
laboratory conditions, the ropes formed a substratum for bacterial biofilm formation and were able to 
bind exogenously added bacteria [129]. Bacteria associated with the ropes were protected from 
antimicrobial drugs, indicating a potential protective role for the bacterial population within ropes. 
Like monomeric EspPα, ropes also bind to HeLa cells [129]. Whether the rope-like structures are 
formed during infection is still elusive. 
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2.6. Gene Expression  
Studies regarding espP gene expression are rare and mostly descriptive. Ebel et al. observed 
enhanced EspP levels in EHEC culture supernatants when bacteria were grown in lysogeny broth (LB) 
medium rather than in minimal essential medium (MEM), indicating that a medium rich in amino acids 
leads to higher EspP production [134]. In addition, more EspP is produced at 37 °C than at  
20 °C [1,134] and pH 7 and pH 9 are favorable compared to pH 5 at which EspP production is nearly 
completely abolished [1]. Based on the methodology used by Ebel et al. and Brunder et al. it is not 
possible to differentiate between effects on gene expression or protein secretion. Enhanced secretion 
under slightly alkaline conditions indicates that EspP might act on the human colon or in the 
circulation. Indeed, we have recently shown a potential interaction of EspP with the human  
intestine [100]. Incubation of EHEC in contact with human intestinal epithelial HCT-8 cells lead to 
upregulation of espP expression up to more than 35-fold [100]. 
3. Conclusions 
EHEC are pathogens that cause severe diseases in humans worldwide. Their pathogenicity is a 
multifactorial process and besides the well-known Shiga toxins, EHEC express a variety of further 
virulence factors. EspP belongs to the SPATE family and has been subject of many studies concerning 
the autotransport mechanism. Thus, its biogenesis has been investigated extensively. The espP gene is 
highly prevalent in EHEC and to date five EspP subtypes are known that differ in their proteolytic 
activity and in their ability to translocate across the bacterial cell membranes. Therefore, mere 
detection of the espP structural gene without subtyping is not sufficient to investigate a potential 
correlation with disease as claimed by some authors. Studies addressing the distribution of EspP 
subtypes indicate that the proteolytic active and translocation-competent subtype EspPα is associated 
with highly pathogenic EHEC serotypes including O157:H7 as well as with isolates from patients with 
severe disease. Hence, nearly all recent studies have been performed (although not always termed 
using subtype nomenclature) with EspPα. This subtype might contribute to biofilm formation possibly 
by the formation of rope-like structures that in addition might protect the bacteria inside these 
structures from host defense. 
As suggested for SPATEs in general, the virulence of EspPα might be mediated by its proteolytic 
activity. Based on the currently available data, EspPα shows pronounced specificity. Notably, EspPα is 
able to cleave another EHEC virulence factor, namely EHEC-Hly. This abolishes the hemolytic and 
cytolytic activity of EHEC-Hly and leads to the suggestion that EHEC bacteria might be able to  
self-control their virulence phenotype by effector molecule interference. In addition, different host 
proteins are degraded by EspPα, e.g. complement factors C3 and C5 as well as coagulation factor V. 
Cleavage of the complement factors significantly reduces complement activation in all activation 
pathways possibly resulting in diminished host response and increased the severity of EHEC 
infections. Degradation of coagulation factor V has been suggested to lead to prolonged bleeding and 
increased hemorrhages during EHEC infection. Functional consequences of FV cleavage have, 
however, not been addressed yet. 
Toxins 2013, 5                          
 
 
38
Based on structural homology and functional similarity, SPATEs have been divided into two 
groups, the cytotoxic class I SPATEs and the non-cytotoxic class II SPATEs [45]. EspP has been 
classified as class I SPATE. Its cytotoxicity is however discussed controversially. The further class I 
SPATEs, Sat, Pet, SigA and EspC, have all been shown to degrade spectrin/fodrin [24,35,45,135] after 
internalization of the host cell and it has been demonstrated that this activity underlies  
cytotoxicity [23,34,41,45] although details in cytotoxic mechanism differ [133,134]. In contrast, EspP, 
like all class II SPATE, does not cleave spectrin/fodrin [44] and available data on cytotoxicity range 
from lack of cytopathic effects to pronounced cytotoxicity. Notably, the potential cytotoxic mechanism 
(which might also explain the controversial results) has not been investigated yet and no data are 
available in support of cellular internalization of EspP. Together, EspP can be regarded as a 
“functional outlier” in the class I SPATE group. 
Coagulation factor V, is also not exclusively cleaved by EspP but in addition also by class I 
SPATEs EspC, Pet, Sat, and the class II SPATEs Pic, and Tsh/Hbp [45]. A further substrate of EspPα, 
pepsin, is cleaved by EpeA, EspC, EspI, Pet, and Pic [22,26,35,45]. Several class II SPATEs show 
mucinolytic activity (EpeA, Pic, and Tsh/Hbp) which is not seen for class I SPATEs including  
EspP [22,35,45]. Interestingly, a recent study provided evidence that Pic degrades various leukocyte 
glycoproteins resulting in impaired chemotaxis and migration. In addition, Tsh/Hbp showed a similar 
substrate spectrum, indicating that class I SPATE might interfere with host response [135]. Although 
via a different pathway, EspP might also affect host response via degradation and inactivation of 
complement factors.  
Together, EspP has been shown to mediate different functions ranging from biofilm formation to 
subversion of host defense. The functional properties of this SPATE are in between the bona fide 
known class I SPATE (cytotoxic via spectrin degradation, no mucinolytic activity) and class II SPATE 
(not cytotoxic, no spectrin degradation, mucinolytic activity, probably interference with host defense). 
It has to be noted that almost all studies have been performed in vitro and their relevance  
in vivo has not been demonstrated yet due to the lack of suitable animal models. Nevertheless, future 
studies will help to understand the function and characteristics of EspP in more detail to further 
elucidate its role as a virulence factor during EHEC infection.  
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